logo

REPL

Replimune GroupยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

REPL Profile

Replimune Group, Inc.

A company that developing oncolytic immunotherapy for the treatment of solid tumor types

Biological Technology
--
07/20/2018
NASDAQ Stock Exchange
479
03-31
Common stock
500 Unicorn Park Drive, Suite 303, Woburn MA 01801
--
Replimune Group, Inc., was incorporated in Delaware in 2015. The company is a clinical-stage biotechnology company dedicated to applying their leading expertise in oncolytic immunotherapy to transform the lives of cancer patients. Use the company's proprietary Immulytic platform to design and develop product candidates designed to maximize the activation of the immune system against cancer.